GlaxoSmithKline PLC (GSK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlaxoSmithKline PLC (GSK) has a cash flow conversion efficiency ratio of 0.141x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX2.22 Billion ≈ $270.35K USD) by net assets (GBX15.75 Billion ≈ $1.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is GlaxoSmithKline PLC's balance sheet to measure how much of total assets are equity-financed.
GlaxoSmithKline PLC - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how GlaxoSmithKline PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GlaxoSmithKline PLC (GSK) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
GlaxoSmithKline PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gr. Sarantis S.A.
AT:SAR
|
0.008x |
|
Pet Valu Holdings Ltd
TO:PET
|
0.363x |
|
Hyundai Development Co
KO:294870
|
-0.110x |
|
Viet Capital Securities JSC
VN:VCI
|
-0.167x |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
-0.007x |
|
Zhejiang Chenfeng Science and Technology Co Ltd Class A
SHG:603685
|
0.026x |
|
United Renewable Energy Co Ltd
TW:3576
|
-0.011x |
|
Troax Group AB
ST:TROAX
|
0.025x |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline PLC (1991–2024)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline PLC from 1991 to 2024. For the full company profile with market capitalisation and key ratios, see GlaxoSmithKline PLC market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX13.09 Billion ≈ $1.59 Million |
GBX6.55 Billion ≈ $797.43K |
0.501x | -5.32% |
| 2023-12-31 | GBX12.79 Billion ≈ $1.56 Million |
GBX6.77 Billion ≈ $823.47K |
0.529x | -27.86% |
| 2022-12-31 | GBX10.10 Billion ≈ $1.23 Million |
GBX7.40 Billion ≈ $900.73K |
0.733x | +96.80% |
| 2021-12-31 | GBX21.34 Billion ≈ $2.60 Million |
GBX7.95 Billion ≈ $967.53K |
0.373x | -8.15% |
| 2020-12-31 | GBX20.81 Billion ≈ $2.53 Million |
GBX8.44 Billion ≈ $1.03 Million |
0.406x | -7.15% |
| 2019-12-31 | GBX18.36 Billion ≈ $2.23 Million |
GBX8.02 Billion ≈ $975.80K |
0.437x | -80.95% |
| 2018-12-31 | GBX3.67 Billion ≈ $446.78K |
GBX8.42 Billion ≈ $1.02 Million |
2.293x | +15.66% |
| 2017-12-31 | GBX3.49 Billion ≈ $424.51K |
GBX6.92 Billion ≈ $841.72K |
1.983x | +51.46% |
| 2016-12-31 | GBX4.96 Billion ≈ $603.85K |
GBX6.50 Billion ≈ $790.50K |
1.309x | +352.40% |
| 2015-12-31 | GBX8.88 Billion ≈ $1.08 Million |
GBX2.57 Billion ≈ $312.57K |
0.289x | -72.41% |
| 2014-12-31 | GBX4.94 Billion ≈ $600.57K |
GBX5.18 Billion ≈ $629.77K |
1.049x | +13.43% |
| 2013-12-31 | GBX7.81 Billion ≈ $950.49K |
GBX7.22 Billion ≈ $878.71K |
0.924x | +42.57% |
| 2012-12-31 | GBX6.75 Billion ≈ $820.91K |
GBX4.38 Billion ≈ $532.31K |
0.648x | -8.42% |
| 2011-12-31 | GBX8.83 Billion ≈ $1.07 Million |
GBX6.25 Billion ≈ $760.44K |
0.708x | +1.52% |
| 2010-12-31 | GBX9.74 Billion ≈ $1.19 Million |
GBX6.80 Billion ≈ $827.00K |
0.697x | -4.45% |
| 2009-12-31 | GBX10.74 Billion ≈ $1.31 Million |
GBX7.84 Billion ≈ $954.02K |
0.730x | -16.95% |
| 2008-12-31 | GBX8.32 Billion ≈ $1.01 Million |
GBX7.31 Billion ≈ $889.54K |
0.879x | +50.31% |
| 2007-12-31 | GBX9.91 Billion ≈ $1.21 Million |
GBX5.79 Billion ≈ $705.08K |
0.585x | +42.54% |
| 2006-12-31 | GBX9.65 Billion ≈ $1.17 Million |
GBX3.96 Billion ≈ $481.57K |
0.410x | -44.42% |
| 2005-12-31 | GBX7.57 Billion ≈ $921.05K |
GBX5.59 Billion ≈ $679.78K |
0.738x | -8.08% |
| 2004-12-31 | GBX5.94 Billion ≈ $722.36K |
GBX4.77 Billion ≈ $580.01K |
0.803x | -3.95% |
| 2003-12-31 | GBX5.80 Billion ≈ $706.18K |
GBX4.85 Billion ≈ $590.33K |
0.836x | +101.83% |
| 2002-12-31 | GBX7.39 Billion ≈ $898.91K |
GBX3.06 Billion ≈ $372.31K |
0.414x | -24.54% |
| 2001-12-31 | GBX8.40 Billion ≈ $1.02 Million |
GBX4.61 Billion ≈ $560.79K |
0.549x | +165.41% |
| 2000-12-31 | GBX8.96 Billion ≈ $1.09 Million |
GBX1.85 Billion ≈ $225.33K |
0.207x | +29.48% |
| 1999-12-31 | GBX3.19 Billion ≈ $388.50K |
GBX510.00 Million ≈ $62.05K |
0.160x | +7.83% |
| 1998-12-31 | GBX2.77 Billion ≈ $336.79K |
GBX410.00 Million ≈ $49.89K |
0.148x | -54.48% |
| 1997-12-31 | GBX1.89 Billion ≈ $229.96K |
GBX615.00 Million ≈ $74.83K |
0.325x | -51.44% |
| 1996-12-31 | GBX1.27 Billion ≈ $154.16K |
GBX849.00 Million ≈ $103.30K |
0.670x | -88.17% |
| 1995-12-31 | GBX221.00 Million ≈ $26.89K |
GBX1.25 Billion ≈ $152.33K |
5.665x | +32.94% |
| 1995-06-30 | GBX574.69 Million ≈ $69.92K |
GBX2.45 Billion ≈ $297.98K |
4.261x | +1983.79% |
| 1994-06-30 | GBX5.15 Billion ≈ $626.48K |
GBX1.05 Billion ≈ $128.12K |
0.205x | +2.74% |
| 1993-06-30 | GBX4.66 Billion ≈ $566.62K |
GBX927.00 Million ≈ $112.79K |
0.199x | +10.25% |
| 1992-06-30 | GBX3.64 Billion ≈ $442.76K |
GBX657.00 Million ≈ $79.94K |
0.181x | -3.65% |
| 1991-06-30 | GBX3.28 Billion ≈ $399.32K |
GBX615.00 Million ≈ $74.83K |
0.187x | -- |
About GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more